Polarean Imaging said a first clinical scan utilising its XENOVIEW (xenon Xe 129 hyperpolarized) technology in the US has taken place at Cincinnati Children's Hospital.
A 19-year-old male with cystic fibrosis was scanned using XENOVIEW, it added.
Richard Hullihen, Polarean’s chief executive, said: “This scan ushers in a new era of lung imaging, opening the door to the greater potential of MRI technology in pulmonary medicine.
“We are in discussions with numerous other medical centers about the adoption of this novel technology and expect this ability to view lung ventilation more fully will be available at additional hospitals in the coming months."
XENOVIEW is the only hyperpolarised contrast agent approved by US regulator the FDA for use with magnetic resonance imaging (MRI) for the evaluation of lung ventilation in adults and paediatric patients aged 12 years and older.
Shares rose 5% to 25.5p.